Skip to content
New issue

Have a question about this project? Sign up for a free GitHub account to open an issue and contact its maintainers and the community.

By clicking “Sign up for GitHub”, you agree to our terms of service and privacy statement. We’ll occasionally send you account related emails.

Already on GitHub? Sign in to your account

Gemfibrozil, repaglinide and pioglitazone PBPK models #338

DeniTue opened this issue May 28, 2019 · 1 comment


None yet
2 participants
Copy link

commented May 28, 2019

Dear all,

We have been working on models for DDI prediction, building a network of interacting CYP2C8 and OATP1B1 perpetrator and victim drugs. Three whole-body PBPK models of gemfibrozil, repaglinide and pioglitazone were carefully developed and then evaluated by prediction of clinical DDI studies.

The corresponding manuscript, including comprehensive documentation, has been published online in Clinical Pharmacokinetics and the models as well as PK-Sim projects presenting the predicted DDI studies have been uploaded as Open Systems Pharmacology repositories to GitHub.

Related publication:
Türk D, Hanke N, Wolf S, Frechen S, Eissing T, Wendl T, Schwab M, Lehr T. Physiologically Based Pharmacokinetic Models for Prediction of Complex CYP2C8 and OATP1B1 (SLCO1B1) Drug–Drug–Gene Interactions: A Modeling Network of Gemfibrozil, Repaglinide, Pioglitazone, Rifampicin, Clarithromycin and Itraconazole. Clinical Pharmacokinetics 2019.

All models can be found here.

Best regards,


This comment has been minimized.

Copy link

commented May 28, 2019

Great work! Thanks for that!

Sign up for free to join this conversation on GitHub. Already have an account? Sign in to comment
You can’t perform that action at this time.